The U.S. Food and Drug Administration on Tuesday approved Pfizer Inc's Ibrance, a potential new standard of care for advanced breast cancer, in a regulatory decision that came more than two months earlier than expected. Wall Street has considered the drug, whose chemical name is palbociclib, to be … Read entire story.